NCT06015776 Purinergic Signaling and the Postmenopausal Heart
| NCT ID | NCT06015776 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beth Israel Deaconess Medical Center |
| Condition | Diastolic Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-07-01 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2019-07-01 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing cardiac surgery under cardiopulmonary bypass. Exclusion Criteria: * Refusal to participate * Emergency surgery * Pre-existing heart block * Preexisting atrial fibrillation * Redo surgery * Estrogen or hormone replacement therapy * History of chronic heart failure * History of major kidney disease
Contact & Investigator
Robina Matyal, MD
PRINCIPAL INVESTIGATOR
Beth Israel Deaconess Medical Center, Professor of Anesthesia
Frequently Asked Questions
Who can join the NCT06015776 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 88 Years, studying Diastolic Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06015776 currently recruiting?
Yes, NCT06015776 is actively recruiting participants. Contact the research team at rmatyal1@bidmc.harvard.edu for enrollment information.
Where is the NCT06015776 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06015776 clinical trial?
NCT06015776 is sponsored by Beth Israel Deaconess Medical Center. The principal investigator is Robina Matyal, MD at Beth Israel Deaconess Medical Center, Professor of Anesthesia. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.